Defective STIM-mediated store operated Ca2+ entry in hepatocytes leads to metabolic dysfunction in obesity

Abstract

Defective Ca2+ handling is a key mechanism underlying hepatic endoplasmic reticulum (ER) dysfunction in obesity. ER Ca2+ level is in part monitored by the store-operated Ca2+ entry (SOCE) system, an adaptive mechanism that senses ER luminal Ca2+ concentrations through the STIM proteins and facilitates import of the ion from the extracellular space. Here, we show that hepatocytes from obese mice displayed significantly diminished SOCE as a result of impaired STIM1 translocation, which was associated with aberrant STIM1 O-GlycNAcylation. Primary hepatocytes deficient in STIM1 exhibited elevated cellular stress as well as impaired insulin action, increased glucose production and lipid droplet accumulation. Additionally, mice with acute liver deletion of STIM1 displayed systemic glucose intolerance. Conversely, over-expression of STIM1 in obese mice led to increased SOCE, which was sufficient to improve systemic glucose tolerance. These findings demonstrate that SOCE is an important mechanism for healthy hepatic Ca2+ balance and systemic metabolic control.

Article and author information

Author details

  1. Ana Paula Arruda

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Benedicte Mengel Pers

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Günes Parlakgul

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Ekin Güney

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Ted Goh

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Erika Cagampan

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Grace Yankun Lee

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Renata L Goncalves

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Gökhan S Hotamisligil

    Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    For correspondence
    ghotamis@hsph.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2906-1897

Funding

National Institutes of Health (DK52539)

  • Gökhan S Hotamisligil

Pew Charitable Trusts

  • Ana Paula Arruda

Alfred Benzon Foundation

  • Benedicte Mengel Pers

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All in vivo studies are approved by the Harvard Medical Area Standing Committee on Animals under the protocols #02396 and #04779.

Copyright

© 2017, Arruda et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,617
    views
  • 660
    downloads
  • 49
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ana Paula Arruda
  2. Benedicte Mengel Pers
  3. Günes Parlakgul
  4. Ekin Güney
  5. Ted Goh
  6. Erika Cagampan
  7. Grace Yankun Lee
  8. Renata L Goncalves
  9. Gökhan S Hotamisligil
(2017)
Defective STIM-mediated store operated Ca2+ entry in hepatocytes leads to metabolic dysfunction in obesity
eLife 6:e29968.
https://doi.org/10.7554/eLife.29968

Share this article

https://doi.org/10.7554/eLife.29968

Further reading

    1. Cell Biology
    Giuliana Giamundo, Daniela Intartaglia ... Ivan Conte
    Research Article

    Endosomes have emerged as major signaling hubs where different internalized ligand–receptor complexes are integrated and the outcome of signaling pathways are organized to regulate the strength and specificity of signal transduction events. Ezrin, a major membrane–actin linker that assembles and coordinates macromolecular signaling complexes at membranes, has emerged recently as an important regulator of lysosomal function. Here, we report that endosomal-localized EGFR/Ezrin complex interacts with and triggers the inhibition of the Tuberous Sclerosis Complex (TSC complex) in response to EGF stimuli. This is regulated through activation of the AKT signaling pathway. Loss of Ezrin was not sufficient to repress TSC complex by EGF and culminated in translocation of TSC complex to lysosomes triggering suppression of mTORC1 signaling. Overexpression of constitutively active EZRINT567D is sufficient to relocalize TSC complex to the endosomes and reactivate mTORC1. Our findings identify EZRIN as a critical regulator of autophagy via TSC complex in response to EGF stimuli and establish the central role of early endosomal signaling in the regulation of mTORC1. Consistently, Medaka fish deficient for Ezrin exhibit defective endo-lysosomal pathway, attributable to the compromised EGFR/AKT signaling, ultimately leading to retinal degeneration. Our data identify a pivotal mechanism of endo-lysosomal signaling involving Ezrin and its associated EGFR/TSC complex, which are essential for retinal function.

    1. Cell Biology
    Kelsey R Baron, Samantha Oviedo ... R Luke Wiseman
    Research Article

    Excessive mitochondrial fragmentation is associated with the pathologic mitochondrial dysfunction implicated in the pathogenesis of etiologically diverse diseases, including many neurodegenerative disorders. The integrated stress response (ISR) – comprising the four eIF2α kinases PERK, GCN2, PKR, and HRI – is a prominent stress-responsive signaling pathway that regulates mitochondrial morphology and function in response to diverse types of pathologic insult. This suggests that pharmacologic activation of the ISR represents a potential strategy to mitigate pathologic mitochondrial fragmentation associated with human disease. Here, we show that pharmacologic activation of the ISR kinases HRI or GCN2 promotes adaptive mitochondrial elongation and prevents mitochondrial fragmentation induced by the calcium ionophore ionomycin. Further, we show that pharmacologic activation of the ISR reduces mitochondrial fragmentation and restores basal mitochondrial morphology in patient fibroblasts expressing the pathogenic D414V variant of the pro-fusion mitochondrial GTPase MFN2 associated with neurological dysfunctions, including ataxia, optic atrophy, and sensorineural hearing loss. These results identify pharmacologic activation of ISR kinases as a potential strategy to prevent pathologic mitochondrial fragmentation induced by disease-relevant chemical and genetic insults, further motivating the pursuit of highly selective ISR kinase-activating compounds as a therapeutic strategy to mitigate mitochondrial dysfunction implicated in diverse human diseases.